We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

114 hedge funds and large institutions have $95.1M invested in Ventyx Biosciences in 2025 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 41 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $387K | Put options by funds: $126K

86% more capital invested

Capital invested by funds: $51.1M → $95.1M (+$44M)

0.02% more ownership

Funds ownership: 62.42%62.43% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 34

2% less funds holding

Funds holding: 116114 (-2)

27% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 41

Holders
114
Holders Change
-2
Holders Change %
-1.72%
% of All Funds
1.5%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
32
Increased
30
Reduced
41
Closed
34
Calls
$387K
Puts
$126K
Net Calls
+$261K
Net Calls Change
+$283K
Name Holding Trade Value Shares
Change
Change in
Stake
Point72 Asset Management
1
Point72 Asset Management
Connecticut
$12.6M +$2.68M +1,660,265 +39%
AAA
2
Affinity Asset Advisors
New York
$9.71M +$7.33M +4,536,182 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$6.77M -$567K -350,927 -10%
TCM
4
Tang Capital Management
California
$6.63M
Marshall Wace
5
Marshall Wace
United Kingdom
$5.13M +$3.87M +2,396,823 New
VPC
6
Vestal Point Capital
New York
$4.28M
Citadel Advisors
7
Citadel Advisors
Florida
$3.78M +$601K +372,143 +27%
Millennium Management
8
Millennium Management
New York
$3.01M +$1.9M +1,179,444 +521%
BlackRock
9
BlackRock
New York
$2.93M -$4.96M -3,071,260 -69%
SCM
10
Sio Capital Management
New York
$2.8M -$2.06M -1,274,691 -49%
RG
11
Redmile Group
California
$2.39M -$735K -455,264 -29%
IC
12
Ikarian Capital
Texas
$2.07M -$404K -250,000 -21%
Connor, Clark & Lunn Investment Management (CC&L)
13
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.02M +$119K +73,601 +8%
SAM
14
Sectoral Asset Management
Quebec, Canada
$1.99M +$1.5M +931,620 New
Bank of America
15
Bank of America
North Carolina
$1.79M -$288K -178,262 -18%
MAM
16
Monaco Asset Management
Monaco
$1.63M -$602K -372,553 -33%
AQR Capital Management
17
AQR Capital Management
Connecticut
$1.56M -$243K -150,369 -17%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.52M -$1.21M -751,259 -51%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$1.32M +$129K +79,880 +15%
Goldman Sachs
20
Goldman Sachs
New York
$1.24M -$20.8K -12,884 -2%
SFM
21
Sphera Funds Management
Israel
$1.19M -$738K -456,935 -45%
Morgan Stanley
22
Morgan Stanley
New York
$1.11M -$574K -355,143 -41%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$1.04M +$346K +214,223 +79%
JP Morgan Chase
24
JP Morgan Chase
New York
$980K -$947K -586,222 -56%
Macquarie Group
25
Macquarie Group
Australia
$920K

VTYX Hedge Fund Activity: Q2 2025 in Review

114 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q2 2025, worth a combined $95.1M — up 86% from $51.1M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of VTYX and 32 opened new positions — a net loss of 2 holders — while 41 trimmed existing stakes and 30 added.

The largest buyer was Affinity Asset Advisors, opening a new position worth an estimated $7.33M. The largest seller was BlackRock, cutting an estimated $4.96M.

  • 114 institutional investors held Ventyx Biosciences (VTYX) as of Q2 2025, down from 116 in Q1 2025.
  • Funds reported $95.1M of Ventyx Biosciences stock for Q2 2025, up 86% quarter-over-quarter.
  • 32 funds opened new Ventyx Biosciences positions in Q2 2025 and 34 closed out, a net change of -2 holders.
  • The largest Ventyx Biosciences buyer in Q2 2025 was Affinity Asset Advisors, an estimated $7.33M added.
  • The largest Ventyx Biosciences seller in Q2 2025 was BlackRock, an estimated $4.96M sold.

Based on aggregated 13F filings for Q2 2025.